What is Intellia Therapeutics's stock issuance proceeds?

Intellia Therapeutics (NTLA) reported stock issuance proceeds of $194.6M in Q2 2026.

What is the long-term trend for Intellia Therapeutics's stock issuance proceeds?

Over 2 years (2023 to 2025), Intellia Therapeutics's stock issuance proceeds has grown at a 3.4% compound annual growth rate (CAGR), from $119.8M to $128.18M.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Intellia Therapeutics NTLA Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Ionis PharmaceuticalsIONS

$57.3M+2,457%

ALN

Alnylam PharmaceuticalsALNY

$13.16M-73.3%

CRISPR TherapeuticsCRSP

-$722K-108%

Beam TherapeuticsBEAM

$2.03M+182%

Iovance Biotherapeutics, Inc.IOVA

$98.51M-33.9%

Viridian Therapeutics, Inc.VRDN

$0-100%

Other financials

Income statement

See full

Revenue$15.0M-9.5%

Operating income-$100.5M+16.8%

Net income-$96.2M+15.8%

EPS (diluted)-$0.81+26.4%

Balance sheet

See full

Cash & equivalents$134.7M+6.2%

Total debt$80.5M-32.5%

Total equity$620.9M-20.4%

Total assets$758.8M-23.1%

Cash flow

See full

Operating cash flow-$117.3M+21.2%

CapEx$79.0K-89.3%

Free cash flow-$117.4M+21.5%

Valuation

See full

Market cap$2.17B+106%

Profitability

See full

Operating margin-636.6%-202pp

Net margin-597%-194pp

FCF margin-550.2%-140pp

Returns & leverage

See full

Return on equity-56.3%-1.5pp

Debt / equity0.1×0.0×

Current ratio6.1×+1.2×

Where this comes from

Reported directly by Intellia Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellia Therapeutics's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Intellia Therapeutics's stock issuance proceeds?: Intellia Therapeutics (NTLA) reported stock issuance proceeds of $194.6M in Q2 2026.
What is the long-term trend for Intellia Therapeutics's stock issuance proceeds?: Over 2 years (2023 to 2025), Intellia Therapeutics's stock issuance proceeds has grown at a 3.4% compound annual growth rate (CAGR), from $119.8M to $128.18M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.